Ethnic Differences in Oral Antithrombotic Therapy

Haechan Cho; Jeehoon Kang; Hyo-Soo Kim; Kyung Woo Park

doi:10.4070/kcj.2020.0098

Journal List > Korean Circ J > v.50(8) > 1144942

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Cho, Kang, Kim, and Park: Ethnic Differences in Oral Antithrombotic Therapy

Review Article

Korean Circulation Journal 2020; 50(8): 645-657.

Published online: 8 April 2020

DOI: https://doi.org/10.4070/kcj.2020.0098

Ethnic Differences in Oral Antithrombotic Therapy

Haechan Cho, MD

, Jeehoon Kang, MD

, Hyo-Soo Kim, MD

, Kyung Woo Park, MD, PhD

Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.

Correspondence to Kyung Woo Park, MD, PhD. Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. kwparkmd@snu.ac.kr

Received 10 March 2020 Accepted 22 March 2020

The Korean Society of Cardiology

(open-access, https://creativecommons.org/licenses/by-nc/4.0):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Oral antithrombotic therapy (antiplatelet therapy and anticoagulation therapy) is a key element of pharmacotherapy in patients with cardiovascular (CV) disease. Several reports of ethnic differences have suggested that there may be difference therapeutic requirements and response to therapy for antithrombotic therapy. In particular for East Asians, there seems to be a lower incidence of ischemic outcomes and a higher incidence of bleeding outcomes compared to Westerners. The purpose of this review is to describe the ethnicity-related differences in antithrombotic therapy for CV disease and to discuss the need to establish a more effective and targeted antithrombotic treatment strategy in East Asians.

Keywords: Ethnic difference, Oral anthrombotic therapy, Antiplatelet therapy, Anticoagulation

INTRODUCTION

Cardiovascular (CV) disease is the universal leading cause of death for virtually all ethnic groups worldwide. However, the risk of CV disease, its prevalence, natural history, and outcomes can differ vastly according to ethnicity.1)2)3) In addition, treatment policies, therapeutic requirements, and the response to therapy including the incidence of adverse drug reactions may differ among regions and races.4)5)6) Furthermore, an increasing body of evidence has suggested that East Asians may have a different risk-benefit profile for antithrombotic therapy (antiplatelet and anticoagulation therapy), namely a lower risk of thrombosis and an increased risk of bleeding.7)8)9) For example, despite having higher on-clopidogrel platelet reactivity during antiplatelet therapy, East Asian patients showed similar or lower rates of ischemic events after percutaneous coronary intervention (PCI).10)11)12)13)14) Similarly, during anticoagulation using warfarin, despite maintenance of similar international normalized ratios (INRs), the rate of intracranial hemorrhage was reported to be higher in East Asians compared with Westerners, and thus the warfarin maintenance target is recommended at a lower range of INR when used in East Asians.15)16)

RACIAL DIFFERENCES IN EPIDEMIOLOGY

There are several studies that report differences in the incidence of thrombotic and bleeding events according to ethnicity. In a study of California residents using comprehensive hospital discharge data, regardless of gender or whether the cause of the venous thromboembolism (VTE) was secondary or idiopathic, Asians/Pacific Islanders showed the lowest adjusted rates of VTE among various ethnic groups. The prevalence of VTE was 70% lower in Asians/Pacific Islanders compared with African Americans. Other studies also showed that East Asians tended to have a lower incidence of VTE than other races, while African Americans tended to have the highest incidence of VTE.17)18) In another analysis of patients prescribed with clopidogrel after PCI, black race was a strong predictor of stent thrombosis (hazard ratio [HR], 2.07; 95% confidence interval [CI], 1.18–3.63; p=0.011)19) In addition, sub-analysis from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial, a trial that enrolled approximately 15,000 patients with atherothrombosis, showed that CV mortality, ischemic heart disease, and stroke were significantly lower in the Asian population than in the other groups.(Asians vs. Blacks vs. Whites vs. Hispanics: 6.2% vs. 8.6% vs. 7.1% vs. 6.8%, respectively)20) Furthermore, other registry-based PCI studies from Korea and Japan have reported lower incidences of stent thrombosis during the first generation drug-eluting stent era (0.2% per year vs. 0.6% per year).10)11)12)

Contrary to thrombotic events, the risk of bleeding seems to be higher in East Asians compared with Westerners.20)21) In a study of US patients with atrial fibrillation (AF), warfarin-associated intracranial hemorrhage was higher in the Asian population than in Western population, despite a similar INR range.15) The A Correlation between on-ClopidogrEL platelet reactivity and BLEEDing events in PCI-treated patients (ACCEL-BLEED) trial, which examined the relationship between platelet reactivity and bleeding episode among patients receiving PCI, reported that East Asians were more likely to bleed than Westerners with the same platelet reactivity.22)

Taken together, these findings demonstrate that ethnicity may play an important role in the incidence of various thrombotic and bleeding events after antithrombotic therapy. Mostly, Africans (or African Americans) seem to have the highest risk of thrombotic events while East Asians seem to have the highest risk of bleeding.

CLINICAL EVIDENCE FOR RACIAL DIFFERENCE

Aspirin

The use of low-dose aspirin for the primary prevention of CV events remains controversial because the increased risk of bleeding may offset the overall benefit.23)24) Considering the overall increased risk of bleeding in East Asians, this controversy may be especially pertinent to the East Asian population. In a meta-analysis of low-dose aspirin for primary prevention, investigators report a more profound increased risk of intracerebral hemorrhage in Asians compared with non-Asians. The relative risk (RR) of intracerebral hemorrhage in the Asian-populations trials was 1.84 (95% CI, 1.04–3.27; 2 trials), whereas in the non-Asian population trials the risk increase was insignificant (RR, 1.14; 95% CI, 0.89–1.46; 8 trials)25) Likewise, gastrointestinal (GI) bleeding, a clinically relevant adverse effect by aspirin,26)27) occurred more often in East Asians. This can be mostly attributed to the higher prevalence of Helicobacter pylori infection and the genetic variation in relation to cytochrome P450 (CYP450) polymorphism.16)28) In this regard, risk of bleeding risk with aspirin can be minimized with a low-dose strategy. Aspirin given at 75 mg daily is estimated to reduce the risk of GI bleeding by 40% compared with 300 mg daily and by 30% with 150 mg daily.29) This may be one of the reasons why a lower dose of aspirin is prescribed in Asian countries than in the United states where the standard dose of aspirin is 325mg.30) Also, in East Asians, owing to the higher risk of H. pylori infection and the subsequent risk for GI bleeding, it is recommended that a GI-protective agent be used in the presence of risk factors such as old age, prior nonsteroidal anti-inflammatory drugs use, concomitant antiplatelet and anticoagulation use, current smoking, and a prior history of bleeding.27)

P2Y12 receptor inhibitors

Clopidogrel

Ethnic differences in response to platelet P2Y12 receptor inhibitors have been reported in multiple papers. In particular, East Asians are known to have a less profound response to clopidogrel compared to Westerners.31)32) After clopidogrel loading (600 mg), the proportion of patients with high on-treatment platelet reactivity was higher in East Asian than Westerners (40.1–63.5% vs. 20–35%)33)34) However, despite a less robust response to clopidogrel, the rates of ischemic events after PCI is similar or even lower in East Asians compared with Westerners. This phenomenon described as the East Asian Paradox.10)11)12)35) This may explain why clopidogrel is still the most frequently used P2Y12 inhibitor in East Asia (Figure 1).36)37) On the other end of the spectrum is bleeding, which has been reported to be higher in East Asians.22)31)32) In the ACCEL-BLEED study, Bleeding Academic Research Consortium (BARC) bleeding occurred within one month of discharge in approximately 30% of the Korean population. Further, the low platelet response (LPR) cutoff was higher in East Asians than that derived from Westerners, suggesting that with the same platelet response to clopidogrel, East Asians are more likely to be in the LPR group, a group that is about 4 times more likely to experience a BARC type 2 or greater bleeding.33)38)39)40)

Figure 1

Proportion of the usage of P2Y12 inhibitors in USA and South Korea.

Third generation P2Y12 receptor inhibitor

Unlike clopidogrel, third generation P2Y12 inhibitors have been shown to have a more profound antiplatelet effect in the East Asian populations.31) As described earlier, the need for clinical trials in the Asian population is the greatest for these new and very potent P2Y12 inhibitors, since as a population, the risk of ischemia is lower and that of bleeding is higher in East Asians. The Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non–ST-segment Elevation myocardial infarction-2 (n=609) and PLATelet inhibition and patient Outcomes (PLATO) pharmacokinetics (n=6,381) studies showed a similar degree of platelet inhibition in Asians at a dose which was lower than that in the Western population.41) The bioavailability of ticagrelor in East Asians was found to be approximately 39% higher when compared to Westerners. In patients with ST segment elevation myocardial infarction (STEMI), platelet reactivity decreased very effectively in Asians when taking ticagrelor (180 mg for loading dose [LD], 90 mg twice daily for maintenance dose [MD])42) In particular, about 95% of patients were found to be equivalent to LPR (platelet reactivity unit [PRU] <85), when PRU was measured 48 hours after administration. PLATO trial (n=18,624) where patients were randomized 1:1 to ticagrelor (180 mg LD, 90 mg twice daily MD) of clopidogrel (600 mg LD, 75mg once daily MD), showed a 16% decrease in the risk of CV death, myocardial infarction (MI) or stroke in the ticagrelor arm. The benefit observed with ticagrelor treatment within the first 30 days of treatment continued throughout the treatment period up to 12 months.43) In a retrospective subgroup analysis comparing Asian versus non-Asian patients from that study, there was no interaction between ethnicity and treatment effect. The risk of CV death, MI or stroke and major bleeding was comparable in Asian and non-Asian patients.44) However, in the 2 dedicated randomized trials performed in East Asians, the results were quite different (Figure 2). In the PHase the International study of ticagreLor and clinical Outcomes in Asian acute coronary syndrome patients trial, where 801 East Asian (Japanese, Taiwanese, and South Korean) patients with acute coronary syndrome (ACS) were randomized between ticagrelor and clopidogrel, the overall major bleeding rate was 10.3% in the ticagrelor group and 6.8% in the clopidogrel group. In the TIcagrelor versus Clopidogrel in Asian/KOREAn patients with ACS intended for invasive management trial, where 800 Koreans with ACS were randomly assigned to ticagrelor or clopidogrel, clinically significant bleeding was higher in the ticagrelor group compared with the clopidogrel group (11.7% [45/400] vs. 5.3% [21/400]; HR, 2.26; 95% CI, 1.34–3.79; p=0.002).45) Although this study was underpowered for efficacy outcomes, the composite of death from CV causes, MI, or stroke was numerically higher in the ticagrelor arm (9.2% [36/400] vs. 5.8% [23/400]; HR, 1.62; 95% CI, 0.96–2.74; p=0.07).

Figure 2

Comparison of the primary efficacy endpoint from studies which compared clopidogrel vs. potent P2Y12 inhibitors.

ACS = acute coronary syndrome; CI = confidence interval; HR = hazard ratio; PHILO = PHase the International study of ticagreLor and clinical Outcomes in Asian acute coronary syndrome patients; PRASFIT = PRASugrel compared with clopidogrel For Japanese patIenTs; TICA KOREA = TIcagrelor versus Clopidogrel in Asian/KOREAn patients with acute coronary syndrome intended for invasive management; TRILOGY = TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage.

For prasugrel, a pharmacodynamic study in Japan demonstrated that with a decreased LD of 15 mg and a MD of 3.75 mg daily, the antiplatelet effect was achieved significantly faster and stronger than the standard dose of clopidogrel (300 mg LD, 75 mg daily MD).46) The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage-ACS (n=7,243) trial was a study comparing the results of prasugrel 10 mg daily and clopidogrel 75 mg daily with aspirin in non-STEMI patients. In the entire cohort, prasugrel showed excellent propensity (HR, 0.91; 95% CI, 0.79–1.05) in CV death, MI, or stroke, but the opposite result was shown in Asians (HR, 1.19; 95% CI, 0.75–1.89).43) The PRASugrel compared with clopidogrel For Japanese patIenTs with ACS undergoing PCI (n=1,363) trial compared the efficacy of clopidogrel and prasugrel after PCI in the Japanese ACS population. Prasugrel was administered at a dose that was much lower (20 mg LD, 3.75 mg daily MD) than which was studied in the pivotal TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel–Thrombolysis In Myocardial Infarction-38 trial, based on the results of the phase II pharmacodynamic study.47)48) At 24 weeks, ischemic events were numerically lower in the prasugrel compared with the clopidogrel group although the difference did not reach statistical significance due to the small sample size (9.4% vs. 11.8%; HR, 0.77; 95% CI, 0.56–1.07; p=0.12).

Table 1 shows the recommended doses of various P2Y12 inhibitors in the US, Europe, Japan. As described earlier, despite less activation of clopidogrel, the recommended dose in Japan is the same as in the US or Europe, while the dose for prasugrel and ticagrelor is lower in Japan than that recommended in Europe or the US (Table 1).4)5)6)49) Taken together, despite the positive results in pivotal trials performed in mostly Westerners, it remains to be seen whether the newer and more potent antiplatelet agents have a definite benefit in treating ACS patients in East Asia.

Table 1

Recommended dose of P2Y12 receptor inhibitors of Korean, Japanese, American, and European guidelines for acute coronary syndrome

Drug	KSC	JCS	ACC/AHA	ESC
Clopidogrel	75 mg	75 mg	75 mg	75 mg
Prasugrel	60 mg LD; 10 mg MD	20 mg LD; 3.75 mg MD	60 mg LD; 10 mg MD	60 mg LD; 10 mg MD
Ticagrelor	90 mg twice a daily	60 mg twice a daily	90 mg twice a daily	90 mg twice a daily

ACC = American College of Cardiology; AHA = American Heart Association; ESC = European Society of Cardiology; JCS = Japanese Circulation Society; KSC = Korean Society of Cardiology; LD = loading dose; MD = maintenance dose.

Anticoagulant

Warfarin

Warfarin is known to effectively reduce thromboembolism in cardiac arrhythmia such as AF.50)51) In one meta-analysis of 6 clinical trials, warfarin reduced the risk of stroke by up to 64%.52) In contrast to European and American guidelines for AF, where the recommend target INR is 2.0 to 3.0 for warfarin,53)54) the recommended target may be slightly different according to ethnicity.55) In fact in the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation registry, which included 3,621 East Asians (21% of 13,541), investigators found that mean INR was lower in Asians compared with Westerners.(2.0 vs. 2.4).56)

The concerns of using warfarin in Asia are complex. First, East Asians have higher bleeding rates when treated with warfarin. The may be due to higher risk of bleeding per se in East Asians, but it may also be due to the fact that there is a higher variability of INR in Asians when using warfarin. In particular the risk of intracranial hemorrhage seems to be higher in East Asians compared with Westerners (1.75% vs. 0.34%; HR, 4.06; CI, 2.48–6.66; p<0.001).15) Secondly, it is more difficult to maintain the time in therapeutic range (TTR) for warfarin in East Asians. Lower levels of TTR in East Asians may be due to diet, body weight, etc. In a recent global AF cohort of 15,400 patients, mean TTRs for East Asian were 36.0%, which were lower than that for North Americans (50.9%) and Western Europeans (62.4%).57) Some investigators have even suggested that a lower range of INR would be more adequate in Asians.58)59) This is supported by the J-RHYTHM registry, where the suggested appropriate INR target in Asians was 1.6 to 2.6, which is lower than in targets in Westerners.60)

Non-vitamin K antagonists

Several studies have shown that non-vitamin K antagonists oral anticoagulant (NOACs) have a significant benefit over warfarin when used for prevention of stroke in patients with AF. NOACs are more effective, safe, and convenient compared with warfarin, and therefore, its usage is rapidly increasing. Four large-scale pivotal randomized trials (Randomized Evaluation of Long-term anticoagulation therapY, Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation, Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation, and Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation) have been performed with NOACs.61)62)63)64)65) Of the 71,783 patients included in the 4 randomized controlled trials, 7,650 were Asian (mostly East Asian). In a meta-analysis, the efficacy and safety of NOACs at standard dose (dabigatran 150 mg, edoxaban 60 mg, rivaroxaban 20 mg, and apixaban 5 mg) was compared between Asians and Westerners.66) NOACs used at the standard dose significantly reduced stroke/systemic embolic event (SEE) in both Western and Asian subjects. However, the magnitude of effect was more pronounced in Asians. (interaction p=0.045) Stroke/SEE, ischemic stroke, MI, and all-cause mortality were similar between NOACs and warfarin when used at the lower dose in both the Asian and Western populations. Bleeding outcomes were mostly significantly in favor of NOACs regardless of ethnicity. However, for major bleeding, hemorrhagic stroke and GI bleeding, the protective effect was more profound in Asians when using the standard dose of NOACs (interaction p value 0.004, 0.046, 0.041, respectively).67)

One nationwide cohort study in South Korea (n=21,679) demonstrated that reduced dose of NOACs showed similar effectiveness and safety compared with the regular dose in patients with low body weight (50–60 kg; HR, 0.907; 95% CI, 0.775–1.059; p=0.217)68)

The a Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants with ACS-1 trial enrolled patients (n=3,037) with ACS and randomized those patients to either aspirin (100 mg/d) or rivaroxaban (2.5 mg twice daily) on top of a P2Y12 receptor inhibitor (clopidogrel or ticagrelor). Compared with participants from Westerners, those from Asia and Pacific region (about 80% patients from Korean and Japan) had the highest risk of significant bleeding (HR, 3.24; 95% CI, 1.27–8.22; p=0.014) and the numerically lowest risk of ischemic events (HR, 0.44; 95% CI, 0.14–1.37; p=0.156).69)

EXPLANATION FOR RACIAL DIFFERENCES

To explain racial difference, we need a more comprehensive understanding of the process of thrombogenesis. The production of blood clots is controlled by very complex interactions, such as blood cell components, plasma components, and blood vessel walls. It is known that there are various differences between races in the process of thrombogenesis (coagulation, fibrinolysis, and inflammation) (Figure 3).18)70)

Figure 3

Various interactions which affect thrombogenesis.

Differences in platelet function and responsiveness are determined by some genetic factors. Bray et al.71) who previously examined racial differences in patients with coronary artery disease found that epinephrine- and adenosine diphosphonate-induced aggregation and heritability in collagen-induced platelet aggregation was stronger in African Americans compared with Westerners. A cross-sectional study looking at the risk of atherosclerosis in various communities showed that platelet activation markers evaluated by flow cytometry in African Americans were very high.72) Differences are also observed in the coagulation index. Ex vivo experiments showed that African Americans had the highest platelet-fibrin clot.73) There are also genetic factors that affect the activation of antiplatelet agents. It is well-known that clopidogrel activation is very susceptible to levels of the CYP450 enzyme (in particular the CYP2C19 polymorphism).74) There are multiple alleles ('2–'8) of the CYP2C19 which are associated with the loss-of-function and frequency of these alleles differ vastly between different ethnicity. Approximately 30% of Westerners were carriers of the CYP2C19 LoF allele, most of which were '2 allele. On the other hand, about 60% of East Asians were carriers of the LoF alleles, of which about 50% were '2 alleles, and the rest were '3 alleles known to be involved in response to the antiplatelet agent.75) Hispanic races are known to have higher average platelet count than other races, and in this regard to recent study.76)

There are also non-genetic factors that may explain racial differences of thrombogenicity and bleeding tendency. Data from the Multi-Ethnic Study of Atherosclerosis cohort suggests that differences in hemostatic factor and plasma endothelial marker levels seem to coincide with rank ordering of CV risk across racial and ethnic groups. In that study, Western populations showed more thrombogenic and dysfunctional endothelial profiles than did East Asians.77) Likewise, proinflammatory cytokines (e.g., interleukin-6, fibrinogen, and C-reactive protein [CRP]), which are known to be associated with the pro-atherosclerotic phenotype, are be higher in Westerners than in East Asians.78) For example, a Canadian comparison of CRP concentration among 1,250 adults of South Asian, East Asian, Western, and Aboriginal descent revealed significant racial/ethnic differences.79) Mean(±standard error) age- and sex-adjusted CRP concentrations were 1.18±0.13 mg/L in East Asians, 2.06±0.12 mg/L in Westerners. Collectively, the unique genetic and demographic characteristics of East Asians may result in a unique balancing point between ischemia and bleeding, where bleeding risk plays a bigger role in determining both the duration and intensity of antithrombotic therapy.80)

CONCLUSION

Many studies have shown that there are differences in thrombogenicity and bleeding propensity among races. In particular, East Asians seem to have a lower risk of atherothrombotic events and a higher risk of bleeding events compared with the Western population.2)3) Therefore, a ‘one-size-fits-all’ strategy using regimens and doses tested and confirmed in mostly Western populations may not be the optimal treatment strategy for other ethnic groups including East Asians. However, East Asians account for small proportion of most large clinical trials, which consist mainly of Westerners (Table 2). Thus, before mechanically applying the current Western-oriented US and European guidelines, we need studies focused on our region and population characteristics. Furthermore, now in the era of precision and personalized medicine, it may be necessary to pursue efforts to apply genetic data and individualized risk profiles in determining the ideal antithrombotic strategy.

Table 2

Proportion of East Asian populations in large randomized clinical trials of acute coronary syndrome and AF

Study	Etiology	Drug	Total	Asian
TRILOGY	ACS	Prasugrel	7,243	752 (8.1)
TRITON	ACS	Prasugrel	13,608	1,905 (14.0)
PLATO	ACS	Ticagrelor	18,624	1,096 (5.8)
RE-LY	AF	Dabigatran	18,113	2,782 (15.3)
ROCKET AF	AF	Rivaroxaban	14,264	932 (6.5)
ARISTOTLE	AF	Apixaban	18,201	1,993 (10.9)
ENGAGE AF	AF	Edoxaban	20,105	1,943 (9.6)

Values are presented as number (%).

ACS = acute coronary syndrome; AF = atrial fibrillation; ARISTOTLE = Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation; ENGAGE = Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation; PLATO = PLATelet inhibition and patient Outcomes; RE-LY = Randomized Evaluation of Long-term anticoagulation therapY; ROCKET AF = Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation; TRILOGY = TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage; TRITON = TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel.

Notes

Conflicts of Interest: The authors have no financial conflicts of interest.

Author Contributions:

Conceptualization: Kang J, Kim HS, Park KW.
Methodology: Cho H.
Supervision: Park KW.
Writing - original draft: Cho H, Kang J, Park KW.
Writing - review & editing: Kang J, Kim HS, Park KW.

References

1. Chaturvedi N. Ethnic differences in cardiovascular disease. Heart. 2003; 89:681–686. PMID: 12748237.

2. Gasevic D, Ross ES, Lear SA. Ethnic differences in cardiovascular disease risk factors: a systematic review of North American evidence. Can J Cardiol. 2015; 31:1169–1179. PMID: 26239006.

3. Henderson SO, Coetzee GA, Ross RK, Yu MC, Henderson BE. Elevated mortality rates from circulatory disease in African American men and women of Los Angeles County, California--a possible genetic susceptibility? Am J Med Sci. 2000; 320:18–23. PMID: 10910369.

4. Kimura K, Kimura T, Ishihara M, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019; 83:1085–1196. PMID: 30930428.

5. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2016; 68:1082–1115. PMID: 27036918.

6. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39:119–177. PMID: 28886621.

7. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295:180–189. PMID: 16403930.

8. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297:1197–1206. PMID: 17374814.

9. Kang J, Park KW, Palmerini T, et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost. 2019; 119:149–162. PMID: 30597509.

10. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369:667–678. PMID: 17321312.

11. Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009; 119:987–995. PMID: 19204304.

12. Park DW, Yun SC, Lee SW, et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv. 2008; 1:494–503. PMID: 19463351.

13. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009; 103:1339–1343. PMID: 19427425.

14. Park KW, Park JJ, Jeon KH, et al. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovasc Ther. 2012; 30:5–11. PMID: 21129165.

15. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50:309–315. PMID: 17659197.

16. Ma C. Current antithrombotic treatment in East Asia: some perspectives on anticoagulation and antiplatelet therapy. Thromb Haemost. 2012; 107:1014–1018. PMID: 22535432.

17. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res. 2009; 123(Suppl 4):S11–7. PMID: 19303496.

18. Zakai NA, McClure LA. Racial differences in venous thromboembolism. J Thromb Haemost. 2011; 9:1877–1882. PMID: 21797965.

19. Collins SD, Torguson R, Gaglia MA Jr, et al. Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation. 2010; 122:1085–1090. PMID: 20805432.

20. Mak KH, Bhatt DL, Shao M, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J. 2009; 157:658–665. PMID: 19332192.

21. Kitamura A, Nakagawa Y, Sato M, et al. Proportions of stroke subtypes among men and women > or =40 years of age in an urban Japanese city in 1992, 1997, and 2002. Stroke. 2006; 37:1374–1378. PMID: 16690900.

22. Kwon TJ, Tantry US, Park Y, et al. Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. Thromb Haemost. 2016; 115:979–992. PMID: 26790469.

23. Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. preventive services task force. Rockville (MD): Agency for Healthcare Research and Quality;2015.

24. Lei H, Gao Q, Liu SR, Xu J. The benefit and safety of aspirin for primary prevention of ischemic stroke: a meta-analysis of randomized trials. Front Pharmacol. 2016; 7:440. PMID: 27917124.

25. Huang WY, Saver JL, Wu YL, Lin CJ, Lee M, Ovbiagele B. Frequency of intracranial hemorrhage with low-dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta-analysis. JAMA Neurol. 2019; 76:906–914.

26. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest. 2001; 119:39S–63S. PMID: 11157642.

27. Koskinas KC, Räber L, Zanchin T, et al. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv. 2015; 8:e002053. PMID: 25910501.

28. Leong RW. Differences in peptic ulcer between the East and the West. Gastroenterol Clin North Am. 2009; 38:363–379. PMID: 19446264.

29. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000; 321:1183–1187. PMID: 11073508.

30. Goto S, Ikeda Y, Chan JC, et al. Risk-factor profile, drug usage and cardiovascular events within a year in patients with and at high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asian regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry. Heart Asia. 2011; 3:93–98. PMID: 27326003.

31. Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014; 11:597–606. PMID: 25154978.

32. Jeong YH. “East asian paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Curr Cardiol Rep. 2014; 16:485. PMID: 24668607.

33. Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014; 35:209–215. PMID: 24067509.

34. Kim IS, Jeong YH, Tantry US, et al. Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. Am Heart J. 2013; 166:95–103. PMID: 23816027.

35. Huo Y, Jeong YH, Gong Y, et al. 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Sci Bull (Beijing). 2019; 64:166–179.

36. Dayoub EJ, Seigerman M, Tuteja S, et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008–2016. JAMA Intern Med. 2018; 178:943–950. PMID: 29799992.

37. Kim C, Shin DH, Ahn CM, et al. The use pattern and clinical impact of new antiplatelet agents including prasugrel and ticagrelor on 30-day outcomes after acute myocardial infarction in Korea: Korean Health Insurance Review and Assessment Data. Korean Circ J. 2017; 47:888–897. PMID: 29035430.

38. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015; 36:1762–1771. PMID: 25896078.

39. Gurbel PA, Jeong YH, Navarese EP, Tantry US. Platelet-mediated thrombosis: from bench to bedside. Circ Res. 2016; 118:1380–1391. PMID: 27126648.

40. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013; 62:2261–2273. PMID: 24076493.

41. Li J, Tang W, Storey RF, Husted S, Teng R. Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Int J Clin Pharmacol Ther. 2016; 54:666–674. PMID: 27191766.

42. Lee YS, Jin CD, Kim MH, et al. Comparison of prasugrel and ticagrelor antiplatelet effects in korean patients presenting with ST-segment elevation myocardial infarction. Circ J. 2015; 79:1248–1254. PMID: 25959558.

43. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361:1045–1057. PMID: 19717846.

44. Kang HJ, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J. 2015; 169:899–905.e1. PMID: 26027629.

45. Park DW, Kwon O, Jang JS, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation. 2019; 140:1865–1877. PMID: 31553203.

46. Yokoi H, Kimura T, Isshiki T, Ogawa H, Ikeda Y. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thromb Res. 2012; 129:623–628. PMID: 22178576.

47. Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J. 2014; 78:1684–1692. PMID: 24759796.

48. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012; 367:1297–1309. PMID: 22920930.

49. The Korean Society of Cardiology. Guidelines of Antiplatelet Therapy for Patients with Acute Coronary Syndrome [Internet]. Seoul: The Korean Society of Cardiology;2012. cited 2020 Apr 7. Available from https://kaim.or.kr/files/guide/%EC%8B%AC%EC%9E%A5_04.pdf.

50. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154:1449–1457. PMID: 8018000.

51. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008; 118:2029–2037. PMID: 18955670.

52. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146:857–867. PMID: 17577005.

53. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019; 140:e125–51. PMID: 30686041.

54. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37:2893–2962. PMID: 27567408.

55. El Rouby S, Mestres CA, LaDuca FM, Zucker ML. Racial and ethnic differences in warfarin response. J Heart Valve Dis. 2004; 13:15–21. PMID: 14765833.

56. Oh S, Goto S, Accetta G, et al. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry. Int J Cardiol. 2016; 223:543–547. PMID: 27552578.

57. Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY atrial fibrillation registry. Circulation. 2014; 129:1568–1576. PMID: 24463370.

58. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J. 2010; 74:2479–2500. PMID: 20962419.

59. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000; 31:817–821. PMID: 10753981.

60. Inoue H, Okumura K, Atarashi H, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM registry. Circ J. 2013; 77:2264–2270. PMID: 23708863.

61. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014; 111:789–797. PMID: 24500243.

62. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–1151. PMID: 19717844.

63. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–891. PMID: 21830957.

64. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–992. PMID: 21870978.

65. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093–2104. PMID: 24251359.

66. Wang KL, Lip GY, Lin SJ, Chiang CE, Non-Vitamin K. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke. 2015; 46:2555–2561. PMID: 26304863.

67. Chiang CE, Okumura K, Zhang S, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017; 33:345–367. PMID: 28765771.

68. Lee SR, Choi EK, Park CS, et al. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight. J Am Coll Cardiol. 2019; 73:919–931. PMID: 30819360.

69. Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017; 389:1799–1808. PMID: 28325638.

70. Iantorno M, Weintraub WS, Garcia-Garcia HM, et al. Genetic and nongenetic implications of racial variation in response to antiplatelet therapy. Am J Cardiol. 2019; 123:1878–1883. PMID: 30967284.

71. Bray PF, Mathias RA, Faraday N, et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost. 2007; 5:1617–1623. PMID: 17663734.

72. Folsom AR, Aleksic N, Sanhueza A, Boerwinkle E. Risk factor correlates of platelet and leukocyte markers assessed by flow cytometry in a population-based sample. Atherosclerosis. 2009; 205:272–278. PMID: 19124123.

73. Gurbel PA, Bliden KP, Cohen E, et al. Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. Blood Coagul Fibrinolysis. 2008; 19:268–275. PMID: 18469547.

74. Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94:317–323. PMID: 23698643.

75. Jeong YH, Abadilla KA, Tantry US, et al. Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study. J Thromb Haemost. 2013; 11:1194–1197. PMID: 23517020.

76. Schick UM, Jain D, Hodonsky CJ, et al. Genome-wide association study of platelet count identifies ancestry-specific loci in Hispanic/Latino Americans. Am J Hum Genet. 2016; 98:229–242. PMID: 26805783.

77. Lutsey PL, Cushman M, Steffen LM, et al. Plasma hemostatic factors and endothelial markers in four racial/ethnic groups: the MESA study. J Thromb Haemost. 2006; 4:2629–2635. PMID: 17002663.

78. Albert MA. Inflammatory biomarkers, race/ethnicity and cardiovascular disease. Nutr Rev. 2007; 65:S234–8. PMID: 18240555.

79. Anand SS, Razak F, Yi Q, et al. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol. 2004; 24:1509–1515. PMID: 15205215.

80. Kang J, Park KW, Ki YJ, et al. Development and validation of an ischemic and bleeding risk evaluation tool in East Asian patients receiving percutaneous coronary intervention. Thromb Haemost. 2019; 119:1182–1193. PMID: 31079414.

TOOLS

Similar articles